Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Isocam II safety update

This article was originally published in The Gray Sheet

Executive Summary

Isocam II safety update: Preliminary failure analysis by the U.K. Medical Devices Agency (MDA) and Park Medical Systems U.K. Ltd determines that the Isocam II dual-headed nuclear medicine gamma camera is "unsafe for clinical use and will require engineering modifications to render it safe." In light of this, FDA "recommends the immediate removal of the Isocam II from service until further notice," since the manufacturer, Park Medical Systems of Quebec, is no longer in business and Park U.K. does not do business in the U.S. FDA issued a safety alert on the Isocam II on Feb. 13 when MDA reported an incident where a "stainless steel plate from a harmonic drive motor failed, causing an arm of the system to fall into the gantry housing of the device" ("The Gray Sheet" Feb. 23, p. 22)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel